Luteinizing hormone-releasing hormone for prostate cancer in a hemodialysis patient : a case report

An 81-year-old man on chronic hemodialysis was referred to our hospital with urinary difficulty. Transperineal needle biopsy of a hard nodule in the prostate revealed moderately differentiated adenocarcinoma. He was diagnosed to have stage C prostate cancer. A standard dose of luteinizing hormone-re...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Hinyokika kiyo. Acta urologica Japonica. - 1962. - 43(1997), 6 vom: 04. Juni, Seite 421-3
1. Verfasser: Mizusawa, H (VerfasserIn)
Weitere Verfasser: Kontani, K, Okaneya, T, Yoneyama, T
Format: Aufsatz
Sprache:Japanese
Veröffentlicht: 1997
Zugriff auf das übergeordnete Werk:Hinyokika kiyo. Acta urologica Japonica
Schlagworte:Case Reports English Abstract Journal Article Antineoplastic Agents, Hormonal Testosterone 3XMK78S47O Luteinizing Hormone 9002-67-9 Leuprolide EFY6W0M8TG
Beschreibung
Zusammenfassung:An 81-year-old man on chronic hemodialysis was referred to our hospital with urinary difficulty. Transperineal needle biopsy of a hard nodule in the prostate revealed moderately differentiated adenocarcinoma. He was diagnosed to have stage C prostate cancer. A standard dose of luteinizing hormone-releasing hormone (LH-RH) analogue, leuprorelin acetate (3.75 mg), was administered every 4 weeks for 15 months. No adverse effects were observed throughout the period. The clinical response to LH-RH analogue was excellent, with normalization of serum prostate-specific antigen level and relief of dysuria. Thus the standard dosage of LH-RH analogue is considered to be adequate for hemodialysis patients
Beschreibung:Date Completed 15.09.1997
Date Revised 21.11.2013
published: Print
Citation Status MEDLINE
ISSN:0018-1994